Stella Xu - Mar 18, 2022 Form 4 Insider Report for Design Therapeutics, Inc. (DSGN)

Role
Director
Signature
/s/ Mustapha Parekh, Attorney-in-Fact
Stock symbol
DSGN
Transactions as of
Mar 18, 2022
Transactions value $
-$11,266,197
Form type
4
Date filed
3/22/2022, 07:26 PM
Previous filing
Sep 20, 2021
Next filing
Jun 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DSGN Common Stock Sale -$10.5M -552K -11.7% $19.04 4.17M Mar 18, 2022 See footnote F1, F2
transaction DSGN Common Stock Sale -$268K -13.2K -0.32% $20.34 4.16M Mar 18, 2022 See footnote F2, F3
transaction DSGN Common Stock Sale -$456K -24K -0.58% $19.01 4.13M Mar 21, 2022 See footnote F2, F4
transaction DSGN Common Stock Sale -$27.1K -1.46K -0.04% $18.63 4.13M Mar 22, 2022 See footnote F2, F5
holding DSGN Common Stock 10K Mar 18, 2022 By spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.8726, inclusive. The Reporting Person undertakes to provide the Issuer, and security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.
F2 The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C. Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P. Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P., except to the extent of her pecuniary interest.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.70, inclusive. The Reporting Person undertakes to provide the Issuer, and security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.30, inclusive. The Reporting Person undertakes to provide the Issuer, and security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.51 to $18.835, inclusive. The Reporting Person undertakes to provide the Issuer, and security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.